Pharmafile Logo
Pharmafocus logo
Advanced Search

Perjeta

Showing 15 posts of 30 posts found.

AZ image

AstraZeneca diabetes drug approved for use in Scotland

November 11, 2014
Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2

The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …

News
Roche image

New cancer drugs escalate Roche earnings

October 16, 2014
Research and Development, Sales and Marketing Cancer, Herceptin (trastuzumab), Kadcyla, Perjeta, Q3, Roche, ado-trastuzumab emtansine, pertuzumab

Roche’s sales saw solid growth in the first nine months of the year, increased by the firm’s new cancer medicines. …

News
Roche image

Roche’s Perjeta sees ‘impressive’ survival rates

September 29, 2014
Sales and Marketing Cancer, ESMO, Perjeta, Roche, breast, madrid

Roche’s oncology drug Perjeta combined with other medicines can help certain breast cancer patients live longer. This is according to …

News
Herceptin

Herceptin faces UK competition within months

April 11, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biocon, Herceptin, Hospira, Perjeta, breast cancer

Roche’s blockbuster breast cancer drug Herceptin may soon be under threat from copycat treatments after a court in the UK …

News
Roche image

Oncology drives Roche profits

January 30, 2014
Sales and Marketing Actemra, Perjeta, Roche, Swiss, q4

Sales at Roche’s pharma division rose 7% year-on-year in 2013, driven largely by strong performances from its oncology portfolio. Group …

News
Perjeta image

Perjeta becomes first approved drug for early breast cancer

October 1, 2013
Sales and Marketing FDA, Herceptin, Perjeta, Roche

Roche’s Perjeta has become the first preoperative breast cancer drug to be authorised by the FDA after it was granted …

News
Perjeta image

Roche breast cancer drug Perjeta rejected by NICE

August 6, 2013
Sales and Marketing Cancer, NICE, Perjeta, Roche

NICE is not recommending Roche’s next generation breast cancer drug Perjeta as a treatment for a particular type of advanced …

News
fda image

FDA gives Perjeta priority

July 3, 2013
Sales and Marketing FDA, Perjeta, Roche, breast cancer

The FDA has granted priority review status to an application for Roche’s Perjeta to be used before surgery in HER2-positive …

News
Roche image

Perjeta approved in EU

March 7, 2013
Sales and Marketing Perjeta, Roche

Roche’s oncology brand Perjeta has been approved in Europe to treat patients with an aggressive form of breast cancer. The …

News

Perjeta recommended in EU

December 18, 2012
Sales and Marketing CHMP, Cancer, Perjeta, Roche

Roche’s breast cancer treatment Perjeta has been given the thumbs up by the CHMP, paving the way for its approval …

News
Perjec

Perjeta reduces risk of death

December 11, 2012
Sales and Marketing Cancer, Perjeta, Roche

Roche’s cancer drug Perjeta helps reduce the risk of death by 34% in patients with HER2-positive metastatic breast cancer (mBC), …

News
Roche image

Roche winning on Perjeta supply, but running short of Boniva

August 20, 2012
Manufacturing and Production, Sales and Marketing Boniva, Perjeta, Roche, breast cancer

Roche is getting production for its new breast cancer drug Perjeta back on track after some initial teething troubles, but …

News
Roche image

Roche posts strong sales results

July 27, 2012
Sales and Marketing Pegasys, Perjeta, Roche, Zelboraf, dalcetrapib

Roche has published healthy revenue growth for the first half of 2012, but its profits have taken a hit. The …

News
Roche image

Roche’s Perjeta increases survival

June 27, 2012
Research and Development, Sales and Marketing EMA, FDA, Herceptin, Perjeta, Roche, breast cancer

Roche’s new drug Perjeta has scored another trial success by increasing overall survival in certain breast cancer patients. The new …

News

FDA approves Roche’s breast cancer drug

June 11, 2012
Sales and Marketing EMA, FDA, Perjeta, Roche, breast cancer

US regulators have approved Roche’s new breast cancer drug after granting it a priority review to speed up the process. …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025